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Background: Immunization regimens that can elicit broadly 
neutralizing antibodies (bNAbs) in humans would be an effective 
vaccine against HIV-1. Our previous work showed that an 
immunization strategy involving a sequence of Env-based germline 
targeting immunogens that were gradually engineered to resemble 
the native Env protein, successfully elicited bNAb-like antibodies in 
a knock-in mouse carrying the inferred germline PGT121/10-1074 
antibody. Despite this achievement, immunization protocols that elicit 
bNAbs in systems with a polyclonal B cell repertoire have not been 
reported to date. The low frequencies of germline bNAb precursors 
in polyclonal systems hinder their activation by immunization which 
therefore requires high affinity immunogens. In addition, competition 
between different epitope-specific B cells in polyclonal germinal 
centers may frustrate bNAb development.
Methods: Based on our previous results in knock-in mice, we have 
aimed to optimize sequential immunization strategies to elicit bNAbs 
in animal models with polyclonal B cell repertoires
Results: The results of immunization experiments in several animal 
models will be presented.
Conclusions: . 
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Background: A major challenge in HIV-1 vaccine research is the 
elicitation of broadly neutralizing antibodies targeting diverse HIV-1 
isolates. We recently found the fusion peptide (FP), a key element 
of the HIV-1-entry machinery, to be a promising target for HIV-1 
vaccine development. Immunization with FP-coupled to keyhole 
limpet hemocyanin (KLH) and boosted by HIV-1 Env trimer elicited 
cross-clade neutralization in standard vaccine test species. Here we 
optimize murine vaccination regimens to improve the breadth and 
potency of the FP-directed immune response.
Methods: C57BL/6 mice were immunized in two-week intervals with 
either prefusion stabilized HIV-1 Env trimers or FP conjugated either 
to KLH or to the heavy chain fragment of tetanus toxoid. Serum 
samples were collected one week after each immunization and 
assessed for neutralization against viruses containing three prevalent 
FP sequences. Top responders from each immunization regimen 
were selected for hybridoma creation and monoclonal antibody 
production.
Results: Over 90% of the mice immunized with FP-coupled conjugate 
followed by HIV-1 Env trimer boosts showed higher neutralization 
responses when compared to those of the HIV-1 Env trimer-only and 
FP carrier-only groups. Approximately 20% of mice immunized with 
a single FP sequence showed neutralizing activity against viruses 
containing diverse FP sequences. Characterization of the isolated 
monoclonal antibodies is ongoing.
Conclusions: FP-directed immunizations elicited robust immune 
response in mice, with serum neutralization of viruses containing 
three of the most prevalent FP sequences. Tested FP vaccination 
regimens suggest multiple avenues for improving the potency and 
breadth of FP-based HIV-1 neutralizing vaccine responses. 
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